<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158236">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02110693</url>
  </required_header>
  <id_info>
    <org_study_id>CTN 0059</org_study_id>
    <secondary_id>2U10DA013034</secondary_id>
    <nct_id>NCT02110693</nct_id>
  </id_info>
  <brief_title>The Tobacco, Alcohol, Prescription Medication and Other Substances Tool</brief_title>
  <acronym>CTN 0059</acronym>
  <official_title>The TAPS Tool: Screen and Brief Assessment Tool Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Friends Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Friends Research Institute, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to develop and validate a questionnaire to screen and assess
      adult primary care patients for tobacco, alcohol, prescription drug, and drug use and
      problems related to their use.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Diagnostic and Statistical Manual-5 Substance Use Disorder Diagnosis</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured with the Modified Composite International Diagnostic Interview - Substance Abuse Module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Substance Use Problems</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Substance Use</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the Time Line Follow Back interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Alcohol Use</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the Alcohol Use Disorders Identification Test - Consumption Items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of cigarette smoking problems</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by the Fagerstrom Test for Nicotine Dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of smokeless tobacco problems</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Smokeless Tobacco Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substance Use</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Oral Fluid drug testing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Substance Use Disorder</condition>
  <arm_group>
    <arm_group_label>Interview administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interviewer administration of a screening instrument.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Self-administration on tablet computer of screening instrument.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tablet administration</intervention_name>
    <description>Participant will self-administer substance use screening instrument on a tablet computer.</description>
    <arm_group_label>Interview administration</arm_group_label>
    <arm_group_label>Tablet administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interviewer administration</intervention_name>
    <description>Interviewer will administer the substance use screening instrument</description>
    <arm_group_label>Interview administration</arm_group_label>
    <arm_group_label>Tablet administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary care patients

          -  Able to provide informed consent

        Exclusion Criteria:

          -  inability to comprehend spoken English

          -  inability to self-administer the instrument on the tablet computer due to physical
             limitations

          -  previously enrolled in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Schwartz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li-Tzy Wu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer McNeely, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chase Brexton Health Services</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MURDOCK Study</name>
      <address>
        <city>Kannapolis</city>
        <state>North Carolina</state>
        <zip>28081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Substance Use</keyword>
  <keyword>Substance Use Disorder</keyword>
  <keyword>Screening</keyword>
  <keyword>Brief Assessment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
